Oren Gilad
Chief Executive Officer chez APREA THERAPEUTICS, INC.
Fortune : 2 M $ au 31/03/2024
Provenance du réseau au premier degré de Oren Gilad
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 16 | |
Atrin Pharmaceuticals LLC
 Atrin Pharmaceuticals LLC BiotechnologyHealth Technology Atrin Pharmaceuticals LLC engages in discovery and development of proprietary medications. It offers ATRN-502, a p53 activator; and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. The firm also provides Atrize, a platform that offers phenotypic FACS-based screening that is applicable across R&D, clinical applications, and a tool for personalized medicine. The company was founded by Oren Gilad and Kevin D. Smith in 2011 and is headquartered in Doylestown, PA.
4
| Holding Company | Biotechnology | 4 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Oren Gilad via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
| AMGEN INC. | Pharmaceuticals: Major | Director of Finance/CFO Corporate Officer/Principal | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| CELGENE | Biotechnology | Corporate Officer/Principal | |
| JOHNSON & JOHNSON | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Medarex, Inc.
 Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | Miscellaneous Commercial Services | Director of Finance/CFO Director of Finance/CFO | |
| INTEGRA LIFESCIENCES HOLDINGS CORPORATION | Medical Specialties | Director/Board Member Director of Finance/CFO | |
Ernst & Young LLP
 Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Atrin Pharmaceuticals, Inc.
 Atrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 2012, Atrin Pharmaceuticals, Inc. is a DNA Damage Response development company that focuses on a pipeline of products resulting from a series of novel conformationally restricted macrocyclic molecules. Part of Aprea Therapeutics, Inc., the private company is based in Doylestown, PA. Atrin Pharmaceuticals was acquired by Aprea Therapeutics, Inc. on May 16, 2022 for $1.33 million. The company's products have the highest known potency for inhibiting ATR and exhibit ATR selectivity with potential broad therapeutic profile. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal Director/Board Member Director/Board Member Chief Operating Officer | |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer Director/Board Member Director of Finance/CFO | |
| Princeton University | College/University | Corporate Officer/Principal Undergraduate Degree Undergraduate Degree | |
Oxford BioTherapeutics Ltd.
 Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Virion Therapeutics LLC
 Virion Therapeutics LLC BiotechnologyHealth Technology Virion Therapeutics LLC develops chronic viral disease vaccines. It offers ChiVax and ChiVax-gD vaccines. The firm engages in developing immune-based treatments for virally-associated cancers and chronic viral infections. The company was founded by Bernard C. Rudnick, Hildegund C. J. Ertl and Andrew D. Luber in 2018 and is headquartered in Newark, DE. | Biotechnology | Director/Board Member Founder | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin Masters Business Admin | |
Novira Therapeutics LLC
 Novira Therapeutics LLC Pharmaceuticals: MajorHealth Technology Novira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of therapies for the treatment of chronic hepatitis B (CHB) infection. The firm’s novel antiviral drug candidates addresses the limitations of CHB therapies. The company was founded in 2009 by Osvaldo Flores, Ali Munawar and George D. Hartman and is headquartered in Doylestown, PA. | Pharmaceuticals: Major | Chief Executive Officer Chief Operating Officer | |
| Max-Planck-Institute for Molecular Genetics | College/University | Doctorate Degree | |
| The Pennsylvania State University | College/University | Undergraduate Degree | |
| Northwood University (Michigan) | College/University | Masters Business Admin | |
Keiretsu Capital LLC
 Keiretsu Capital LLC Investment ManagersFinance Keiretsu Capital LLC (Keiretsu) is a Venture Capital firm, a subsidiary of Keiretsu Forum LLC founded in 2013 by Matthew le Merle and Randy Williams. The firm headquartered in Seattle, Washington. | Investment Managers | Investment Committee Member | |
Mid-Atlantic Diamond Ventures
 Mid-Atlantic Diamond Ventures Investment ManagersFinance Mid-Atlantic Diamond Ventures operates as an alternative investment manager. The company was founded in 2003 and is headquartered in Philadelphia, PA. | Investment Managers | Founder | |
Sagemedic Corp.
 Sagemedic Corp. Pharmaceuticals: MajorHealth Technology Sagemedic Corp. specializes in precision medicine for cancer patients. The American company's approach is designed to identify the most effective treatment options, overcoming the limitations of genomic testing. Sagemedic was founded by Christian Apfel and Brigitte Apfel, with Christian Apfel serving as CEO since incorporation. | Pharmaceuticals: Major | Director/Board Member | |
| AGILE THERAPEUTICS, INC. | Pharmaceuticals: Major | Director of Finance/CFO | |
| Villanova University | College/University | Undergraduate Degree | |
New Jersey Technology Council
 New Jersey Technology Council Miscellaneous Commercial ServicesCommercial Services New Jersey Technology Council provides business development, education and advocacy services. It serves communications, e-business, multimedia, consumer technologies, manufacturing, engineering and energy sectors. The company was founded in 1996 and is headquartered in New Brunswick, NJ. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
NETRIS Pharma SAS
 NETRIS Pharma SAS BiotechnologyHealth Technology NETRIS Pharma SAS develops targeted therapies for the treatment of cancer. The company is based in Lyon, France. The French company was founded in 2008 by Patrick Mehlen, Agnès Bernet. Patrick Mehlen has been the CEO since 2008. | Biotechnology | Chairman | |
| TRANSGENE | Biotechnology | Director/Board Member | |
| HALOZYME THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
| CELATOR PHARMACEUTICALS INC | Pharmaceuticals: Major | Director/Board Member | |
| University of Nice Sophia Antipolis | College/University | Doctorate Degree | |
| PIERIS PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member | |
Theravectys SAS
 Theravectys SAS BiotechnologyHealth Technology Theravectys SAS provides biotechnology research services. It is working on the development of a therapeutic vaccine against HIV. The company was founded on May 17, 2005 and is headquartered in Paris, France. | Biotechnology | Director/Board Member | |
| European Organisation for Research & Treatment of Cancer | Director/Board Member | ||
| VALERIO THERAPEUTICS | Pharmaceuticals: Major | Director/Board Member | |
Institut de Recherches Internationales Servier
 Institut de Recherches Internationales Servier Miscellaneous Commercial ServicesCommercial Services Part of Servier SAS, Institut de Recherches Internationales Servier is a French company that provides scientific research and development services. The private company is based in Suresnes, France. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Immunomic Therapeutics, Inc.
 Immunomic Therapeutics, Inc. BiotechnologyHealth Technology Immunomic Therapeutics, Inc. engages in the discovery and development of drugs. The firm specializes in DNA vaccines, lamp technology, allergy, oncology, animal health and infectious diseases. The company was founded by William G. Hearl, Bernard C. Rudnick and Thomas J. August and is headquartered in Rockville, MD. | Biotechnology | Founder | |
| Sanofi-Aventis Pharmaceuticals | Corporate Officer/Principal | ||
iTeos Therapeutics SA
 iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Pharmaceuticals: Major | Director/Board Member | |
Synergie Lyon Cancer
 Synergie Lyon Cancer Miscellaneous Commercial ServicesCommercial Services Synergie Lyon Cancer provides health care services. It focuses on research efforts on cancer escape, apoptosis and senescence and Immune surveillance. The company was founded in 2007 and is headquartered in Lyon, France. | Miscellaneous Commercial Services | President | |
| COMPUGEN LTD. | Biotechnology | Director/Board Member |
Statistiques
Internationale
| Etats-Unis | 29 |
| France | 8 |
| Belgique | 3 |
| Chine | 2 |
| Suède | 2 |
Sectorielle
| Health Technology | 25 |
| Consumer Services | 8 |
| Commercial Services | 6 |
| Finance | 3 |
| Process Industries | 2 |
Opérationnelle
| Director/Board Member | 97 |
| Corporate Officer/Principal | 51 |
| Independent Dir/Board Member | 38 |
| Director of Finance/CFO | 28 |
| President | 20 |
Relations les plus connectées
| Insiders | |
|---|---|
| Jean Bizzari | 24 |
| Bernd Seizinger | 23 |
| Michael Kelly | 19 |
| Christian Schade | 16 |
| Richard Peters | 16 |
| Bernard Rudnick | 16 |
| Marc Duey | 15 |
| Jeffrey Dayno | 14 |
| John Hamill | 13 |
| John Henneman | 13 |
| Rifat Pamukcu | 12 |
| Michael Grissinger | 12 |
| Lars Abrahmsén | 11 |
| Gabriela Gruia | 8 |
| Scott Coiante | 7 |
- Bourse
- Insiders
- Oren Gilad
- Connexions Sociétés
